Multi-Targeted histone deacetylase inhibitors in cancer therapy

Current Medicinal Chemistry

Volumn 19, Issue 4, 2012, Pages 475-487

  Ai, T ^a   Cui, H ^a   Chen, L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer therapy; Chronic myelogenous leukemia; Drug discovery; Drug resistance; Dual inhibitor; Histone deacetylase; Histone deacetylase inhibitors; Inosine monophosphate dehydrogenase; Multi targeted inhibitor; Protein kinase

Indexed keywords

4 PHENYLBUTYRIC ACID; BELINOSTAT; BMS 337197; BUTYRIC ACID; CARBOPLATIN; CISPLATIN; DACINOSTAT; DASATINIB; ENTINOSTAT; ERLOTINIB; FOLIC ACID; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INOSINATE DEHYDROGENASE INHIBITOR; MASITINIB; MERIMEPODIB; MOCETINOSTAT; MYCOPHENOLIC ACID; NILOTINIB; PACLITAXEL; PANOBINOSTAT; RETINOIC ACID; ROMIDEPSIN; SORAFENIB; THIOCOLCHICOSIDE; TIAZOFURIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; VX 148;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN K 562; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENDOMETRIUM CANCER; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MICROTUBULE ASSEMBLY; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863232466     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712798918842     Document Type: Article

References (78)

1. Rowley, J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973, 243, 290-293.
2. Stegmeier, F.; Warmuth, M.; Sellers, W.R.; Dorsch, M. Targeted cancer therapies in the twenty-first century: Lessons from imatinib. Clin. Pharmacol. Ther., 2010, 87, 543-552.
3. Schenone, S.; Brullo, C.; Botta, M. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: Tyrosine kinase inhibitors and molecules that act by alternative mechanisms. Curr. Med. Chem., 2010, 17, 1220-1245.
4. Quintas-Cardama, A.; Cortes, J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood, 2009, 113, 1619-1630.
5. Lee, T.S.; Potts, S.J.; Kantarjian, H.; Cortes, J.; Giles, F.; Albitar, M. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer, 2008, 112, 1744-1753. (Pubitemid 351536834)
6. Lu, X.Y.; Cai, Q.; Ding, K. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation. Curr. Med. Chem., 2011, 18, 2146-2157.
7. Soverini, S.; Iacobucci, I.; Baccarani, M.; Martinelli, G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica, 2007, 92, 437-439. (Pubitemid 350144288)
8. Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S.M.; Fu, B.; Lin, M.T.; Calhoun, E.S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Hidalgo, M.; Leach, S.D.; Klein, A.P.; Jaffee, E.M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J.R.; Kern, S.E.; Hruban, R.H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008, 321, 1801-1806.
9. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov., 2004, 3, 1001-1010. (Pubitemid 39642363)
10. Ma, X.; Ezzeldin, H.H.; Diasio, R.B. Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs, 2009, 69, 1911-1934.
11. Marks, P.A.; Xu, W.S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem., 2009, 107, 600-608.
12. Witt, O.; Deubzer, H.E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett., 2009, 277, 8-21.
13. Venugopal, B.; Evans, T.R. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem., 2011, 18, 1658-1671.
14. Gui, C.Y.; Ngo, L.; Xu, W.S.; Richon, V.M.; Marks, P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 1241-1246. (Pubitemid 38182673)
15. Kim, M.S.; Kwon, H.J.; Lee, Y.M.; Baek, J.H.; Jang, J.E.; Lee, S.W.; Moon, E.J.; Kim, H.S.; Lee, S.K.; Chung, H.Y.; Kim, C.W.; Kim, K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med., 2001, 7, 437-443. (Pubitemid 32298546)
16. Marks, P.A. Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta, 2010, 1799, 717-725.
17. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Disc., 2006, 5, 769-784. (Pubitemid 44348499)
18. Kovacs, J.J.; Murphy, P.J.; Gaillard, S.; Zhao, X.; Wu, J.T.; Nicchitta, C.V.; Yoshida, M.; Toft, D.O.; Pratt, W.B.; Yao, T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell, 2005, 18, 601-607. (Pubitemid 40726236)
19. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem., 2005, 280, 26729-26734. (Pubitemid 41040705)
20. Bots, M.; Johnstone, R.W. Rational combinations using HDAC inhibitors. Clin. Cancer Res., 2009, 15, 3970-3977.
21. Bertrand, P. Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem., 2010, 45, 2095-2116.
22. Miller, T.A.; Witter, D.J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem., 2003, 46, 5097-5116. (Pubitemid 37414179)
23. Itoh, Y.; Suzuki, T.; Miyata, N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des., 2008, 14, 529-544. (Pubitemid 351516877)
24. Butler, K.V.; Kozikowski, A.P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des., 2008, 14, 505-528. (Pubitemid 351516876)
25. Canzoneri, J.C.; Chen, P.C.; Oyelere, A.K. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide. Bioorg. Med. Chem. Lett., 2009, 19, 6588-6590.
26. Varghese, S.; Gupta, D.; Baran, T.; Jiemjit, A.; Gore, S.D.; Casero, R.A.; Woster, P.M. Alkyl-substituted polyaminohydroxamic acids: A novel class of targeted histone deacetylase inhibitors. J. Med. Chem., 2005, 48, 6350-6365. (Pubitemid 41428987)
27. Boncher, T.; Bi, X.; Varghese, S.; Casero, R.A., Jr.; Woster, P.M. Polyamine-based analogues as biochemical probes and potential therapeutics. Biochem. Soc. Trans., 2007, 35, 356-363. (Pubitemid 46596508)
28. Varghese, S.; Senanayake, T.; Murray-Stewart, T.; Doering, K.; Fraser, A.; Casero, R.A., Jr.; Woster, P.M. Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors. J. Med. Chem., 2008, 51, 2447-2456. (Pubitemid 351628506)
29. Reddy, J.A.; Allagadda, V.M.; Leamon, C.P. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol., 2005, 6, 131-150. (Pubitemid 40637386)
30. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 3313-3317. (Pubitemid 38624614)
31. Suzuki, T.; Hisakawa, S.; Itoh, Y.; Suzuki, N.; Takahashi, K.; Kawahata, M.; Yamaguchi, K.; Nakagawa, H.; Miyata, N. Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 4208-4212. (Pubitemid 47028601)
32. Carrasco, M.P.; Enyedy, E.A.; Krupenko, N.I.; Krupenko, S.A.; Nuti, E.; Tuccinardi, T.; Santamaria, S.; Rossello, A.; Martinelli, A.; Santos, M.A. Novel folate-hydroxamate based antimetabolites: Synthesis and biological evaluation. Med. Chem., 2011, 7, 265-274.
33. Petrie, K.; Zelent, A.; Waxman, S. Differentiation therapy of acute myeloid leukemia: Past, present and future. Curr. Opin. Hematol., 2009, 16, 84-91.
34. Claus, R.; Lubbert, M. Epigenetic targets in hematopoietic malignancies. Oncogene, 2003, 22, 6489-6496. (Pubitemid 37372329)
35. Ferrara, F.F.; Fazi, F.; Bianchini, A.; Padula, F.; Gelmetti, V.; Minucci, S.; Mancini, M.; Pelicci, P.G.; Lo Coco, F.; Nervi, C. Histone deacetylasetargeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 2001, 61, 2-7. (Pubitemid 32095688)
36. Cote, S.; Rosenauer, A.; Bianchini, A.; Seiter, K.; Vandewiele, J.; Nervi, C.; Miller, W.H., Jr. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood, 2002, 100, 2586-2596.
37. Nudelman, A.; Rephaeli, A. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J. Med. Chem., 2000, 43, 2962-2966. (Pubitemid 30599654)
38. Mann, K.K.; Rephaeli, A.; Colosimo, A.L.; Diaz, Z.; Nudelman, A.; Levovich, I.; Jing, Y.; Waxman, S.; Miller, W.H., Jr. A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol. Cancer Res., 2003, 1, 903-912. (Pubitemid 37288708)
39. Gediya, L.K.; Khandelwal, A.; Patel, J.; Belosay, A.; Sabnis, G.; Mehta, J.; Purushottamachar, P.; Njar, V.C. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. J. Med. Chem., 2008, 51, 3895-3904. (Pubitemid 351956518)
40. Risinger, A.L.; Giles, F.J.; Mooberry, S.L. Microtubule dynamics as a target in oncology. Cancer Treat. Rev., 2009, 35, 255-261.
41. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J., 2003, 22, 1168-1179. (Pubitemid 36313600)
42. Dowdy, S.C.; Jiang, S.; Zhou, X.C.; Hou, X.; Jin, F.; Podratz, K.C.; Jiang, S.W. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther., 2006, 5, 2767-2776. (Pubitemid 44849003)
43. Catalano, M.G.; Poli, R.; Pugliese, M.; Fortunati, N.; Boccuzzi, G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer, 2007, 14, 839-845. (Pubitemid 350074071)
44. Ramalingam, S.S.; Maitland, M.L.; Frankel, P.; Argiris, A.E.; Koczywas, M.; Gitlitz, B.; Thomas, S.; Espinoza-Delgado, I.; Vokes, E.E.; Gandara, D.R.; Belani, C.P. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol., 2010, 28, 56-62.
45. Passarella, D.; Comi, D.; Vanossi, A.; Paganini, G.; Colombo, F.; Ferrante, L.; Zuco, V.; Danieli, B.; Zunino, F. Histone deacetylase and microtubules as targets for the synthesis of releasable conjugate compounds. Bioorg. Med. Chem. Lett., 2009, 19, 6358-6363.
46. Galanski, M. Recent developments in the field of anticancer platinum complexes. Recent Pat. Anticancer Drug Discov., 2006, 1, 285-295.
47. Griffith, D.; Morgan, M.P.; Marmion, C.J. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem. Commun., 2009, 6735-6737.
48. Glaser, K.B. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem. Pharmacol., 2007, 74, 659-671. (Pubitemid 47096639)
49. Soria, J.C.; Massard, C.; Magne, N.; Bader, T.; Mansfield, C.D.; Blay, J.Y.; Bui, B.N.; Moussy, A.; Hermine, O.; Armand, J.P. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur. J. Cancer, 2009, 45, 2333-2341.
50. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of chimeric histone deacetylase-and tyrosine kinase-inhibitors: A series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. J. Med. Chem., 2009, 52, 2265-2279.
51. Uecker, A.; Sicker, M.; Beckers, T.; Mahboobi, S.; Hagerstrand, D.; Ostman, A.; Bohmer, F.D. Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents. Anticancer Drugs, 2010, 21, 759-765.
52. Cai, X.; Zhai, H.X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin- 6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53, 2000-2009.
53. Ghose, A.K.; Herbertz, T.; Pippin, D.A.; Salvino, J.M.; Mallamo, J.P. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J. Med. Chem., 2008, 51, 5149-5171.
54. Liao, J.J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem., 2007, 50, 409-424. (Pubitemid 46239775)
55. Lai, C.J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D.G.; Yin, L.; Samson, M.; Forrester, J.; Zifcak, B.; Xu, G.X.; DellaRocca, S.; Zhai, H.X.; Cai, X.; Munger, W.E.; Keegan, M.; Pepicelli, C.V.; Qian, C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res., 2010, 70, 3647-3656.
56. Mahboobi, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J. Med. Chem., 2010, 53, 8546-8555.
57. Hedstrom, L. IMP dehydrogenase: Structure, mechanism, and inhibition. Chem. Rev., 2009, 109, 2903-2928.
58. Chen, L.; Pankiewicz, K.W. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr. Opin. Drug Discov. Devel., 2007, 10, 403-412. (Pubitemid 47093123)
59. Chen, L.; Petrelli, R.; Felczak, K.; Gao, G.; Bonnac, L.; Yu, J.S.; Bennett, E.M.; Pankiewicz, K.W. Nicotinamide adenine dinucleotide based therapeutics. Curr. Med. Chem., 2008, 15, 650-670. (Pubitemid 351516802)
60. Sintchak, M.D.; Nimmesgern, E. The structure of inosine 5 '-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology, 2000, 47, 163-184. (Pubitemid 30394537)
61. Jain, J.; Almquist, S.J.; Heiser, A.D.; Shlyakhter, D.; Leon, E.; Memmott, C.; Moody, C.S.; Nimmesgern, E.; Decker, C. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J. Pharmacol. Exp. Ther., 2002, 302, 1272-1277. (Pubitemid 34920252)
62. Dhar, T.G.M.; Shen, Z.Q.; Fleener, C.A.; Rouleau, K.A.; Barrish, J.C.; Hollenbaugh, D.L.; Iwanowicz, E.J. The TosMIC approach to 3-(oxazol-5-yl) indoles: Application to the synthesis of indole-based IMPDH inhibitors. Bioorg. Med. Chem. Lett., 2002, 12, 3305-3308. (Pubitemid 35248236)
63. Dhar, T.G.M.; Shen, Z.Q.; Gu, H.H.; Chen, P.; Norris, D.; Watterson, S.H.; Ballentine, S.K.; Fleener, C.A.; Rouleau, K.A.; Barrish, J.C.; Townsend, R.; Hollenbaugh, D.L.; Iwanowicz, E.J. 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: Synthesis and initial structureactivity relationships. Bioorg. Med. Chem. Lett., 2003, 13, 3557-3560. (Pubitemid 37141429)
64. Chen, P.; Norris, D.; Haslow, K.D.; Dhar, T.G.M.; Pitts, W.J.; Watterson, S.H.; Cheney, D.L.; Bassolino, D.A.; Fleener, C.A.; Rouleau, K.A.; Hollenbaugh, D.L.; Townsend, R.M.; Barrish, J.C.; Iwanowicz, E.J. Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 1345-1348. (Pubitemid 36351349)
65. Watterson, S.H.; Chen, P.; Zhao, Y.; Gu, H.H.; Dhar, T.G.; Xiao, Z.; Ballentine, S.K.; Shen, Z.; Fleener, C.A.; Rouleau, K.A.; Obermeier, M.; Yang, Z.; McIntyre, K.W.; Shuster, D.J.; Witmer, M.; Dambach, D.; Chao, S.; Mathur, A.; Chen, B.C.; Barrish, J.C.; Robl, J.A.; Townsend, R.; Iwanowicz, E.J. Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: Discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin- 3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419). J. Med. Chem., 2007, 50, 3730-3742. (Pubitemid 47195479)
66. Watterson, S.H.; Liu, C.J.; Dhar, T.G.M.; Gu, H.H.; Pitts, W.J.; Barrish, J.C.; Fleener, C.A.; Rouleau, K.; Sherbina, N.Z.; Hollenbaugh, D.L.; Iwanowicz, E.J. Novel amide-based inhibitors of inosine 5 '-monophosphate dehydrogenase. Bioorg. Med. Chem. Lett., 2002, 12, 2879-2882. (Pubitemid 35266754)
67. Gu, H.H.; Iwanowicz, E.J.; Guo, J.Q.; Watterson, S.H.; Shen, Z.Q.; Pitts, W.J.; Dhar, T.G.M.; Fleener, C.A.; Rouleau, K.; Sherbina, N.Z.; Witmer, M.; Tredup, J.; Hollenbaugh, D. Novel diamide-based inhibitors of IMPDH. Bioorg. Med. Chem. Lett., 2002, 12, 1323-1326. (Pubitemid 34327509)
68. Iwanowicz, E.J.; Watterson, S.H.; Liu, C.J.; Gu, H.H.; Mitt, T.; Leftheris, K.; Barrish, J.C.; Fleener, C.A.; Rouleau, K.; Sherbina, N.Z.; Hollenbaugh, D.L. Novel guanidine-based inhibitors of inosine monophosphate dehydrogenase. Bioorg. Med. Chem. Lett., 2002, 12, 2931-2934. (Pubitemid 35266762)
69. Pitts, W.J.; Guo, J.Q.; Dhar, T.G.M.; Shen, Z.Q.; Gu, H.H.; Watterson, S.H.; Bednarz, M.S.; Chen, B.C.; Barrish, J.C.; Bassolino, D.; Cheney, D.; Fleener, C.A.; Rouleau, K.A.; Hollenbaugh, D.L.; Iwanowicz, E.J. Rapid synthesis oftriazine inhibitors of inosine monophosphate dehydrogenase. Bioorg. Med. Chem. Lett., 2002, 12, 2137-2140. (Pubitemid 34804384)
70. Iwanowicz, E.J.; Watterson, S.H.; Guo, J.Q.; Pitts, W.J.; Dhar, T.G.M.; Shen, Z.Q.; Chen, P.; Gu, H.H.; Fleener, C.A.; Rouleau, K.A.; Cheney, D.L.; Townsend, R.M.; Hollenbaugh, D.L. Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-3-methoxy-4-(5-oxazolyl)phenyl moiety. Bioorg. Med. Chem. Lett., 2003, 13, 2059-2063. (Pubitemid 36638410)
71. Dhar, T.G.M.; Shen, Z.Q.; Guo, J.Q.; Liu, C.J.; Watterson, S.H.; Gu, H.H.; Pitts, W.J.; Fleener, C.A.; Rouleau, K.A.; Sherbina, N.Z.; McIntyre, K.W.; Shuster, D.J.; Witmer, M.R.; Tredup, J.A.; Chen, B.C.; Zhao, R.L.; Bednarz, M.S.; Cheney, D.L.; MacMaster, J.F.; Miller, L.M.; Berry, K.K.; Harper, T.W.; Barrish, J.C.; Hollenbaugh, D.L.; Iwanowicz, E.J. Discovery of N-2-2-3-methoxy-4-(5-oxazolyl)phenyl amino -5-oxazolyl phenyl -N-methyl-4-morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase (IMPDH) with excellent in vivo activity. J. Med. Chem., 2002, 45, 2127-2130. (Pubitemid 34525792)
72. Watterson, S.H.; Carlsen, M.; Dhar, T.G.M.; Shen, Z.Q.; Pitts, W.J.; Guo, J.Q.; Gu, H.H.; Norris, D.; Chorba, J.; Chen, P.; Cheney, D.; Witmer, M.; Fleener, C.A.; Rouleau, K.; Townsend, R.; Hollenbaugh, D.L.; Iwanowicz, E.J. Novel inhibitors of IMPDH: A highly potent and selective quinolonebased series. Bioorg. Med. Chem. Lett., 2003, 13, 543-546. (Pubitemid 36259731)
73. Watterson, S.H.; Dhar, T.G.M.; Ballentine, S.K.; Shen, Z.Q.; Barrish, J.C.; Cheney, D.; Fleener, C.A.; Rouleau, K.A.; Townsend, R.; Hollenbaugh, D.L.; Iwanowicz, E.J. Novel indole-based inhibitors of IMPDH: Introduction of hydrogen bond acceptors at indole C-3. Bioorg. Med. Chem. Lett., 2003, 13, 1273-1276. (Pubitemid 36351332)
74. Buckley, G.M.; Davies, N.; Dyke, H.J.; Gilbert, P.J.; Hannah, D.R.; Haughan, A.F.; Hunt, C.A.; Pitt, W.R.; Profit, R.H.; Ray, N.C.; Richard, M.D.; Sharpe, A.; Taylor, A.J.; Whitworth, J.M.; Williams, S.C. Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: Synthesis and initial structure-activity relationships. Bioorg. Med. Chem. Lett., 2005, 15, 751-754. (Pubitemid 40143160)
75. Chen, L.; Wilson, D.; Jayaram, H.N.; Pankiewicz, K.W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J. Med. Chem., 2007, 50, 6685-6691. (Pubitemid 350309105)
76. Batovska, D.I.; Kim, D.H.; Mitsuhashi, S.; Cho, Y.S.; Kwon, H.J.; Ubukata, M. Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level. Biosci. Biotechnol. Biochem., 2008, 72, 2623-2631.
77. Mitsuhashi, S.; Takenaka, J.; Iwamori, K.; Nakajima, N.; Ubukata, M. Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycophenolic acid derivatives. Bioorg. Med. Chem., 2010, 18, 8106-8111.
78. Chen, L.; Petrelli, R.; Gao, G.; Wilson, D.J.; McLean, G.T.; Jayaram, H.N.; Sham, Y.Y.; Pankiewicz, K.W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg. Med. Chem., 2010, 18, 5950-5964.